Literature DB >> 22885475

Serum markers for predicting significant necroinflammatory activity in patients with chronic hepatitis B.

Hyo Jung Cho1, Soon Sun Kim, Seun Joo Ahn, Chang Bum Bae, Han Gyeol Kim, Young Jip Kim, Seung Kyung Lee, Ga Won Song, Dong Joon Kim, Seong Gyu Hwang, Jin Mo Yang, Young Bae Kim, Young Nyun Park, Sung Won Cho, Jae Youn Cheong.   

Abstract

OBJECTIVES: The aim of this study was to determine the serum markers that predict significant inflammation in patients with chronic hepatitis B (CHB). DESIGN AND METHODS: Between October 2005 and June 2009, 384 subjects with CHB were enrolled.
RESULTS: Multiple logistic regression analysis identified the ALT, hyaluronic acid (HA) and procollagen III N-terminal peptide (PIIINP) as independent predictors of significant inflammation (grade≥3). We constructed a formula for predicting significant inflammation. A significant inflammation (SI) score=1.773×ALT score+1.599×PIIINP score+0.677×HA score-1.962. The area under receiver operating characteristic curve of the SI score was 0.831. The sensitivity, specificity, positive predictive value and negative predictive value of the SI score were 79.5%, 70.8%, 76.8% and 74.3%, respectively.
CONCLUSIONS: A simple scoring system including ALT, PIIINP and HA is an accurate non-invasive predictor of significant inflammatory activities in patients with CHB.
Copyright © 2012 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22885475     DOI: 10.1016/j.clinbiochem.2012.07.107

Source DB:  PubMed          Journal:  Clin Biochem        ISSN: 0009-9120            Impact factor:   3.281


  3 in total

1.  Liver stiffness measurement-based scoring system for significant inflammation related to chronic hepatitis B.

Authors:  Mei-Zhu Hong; Ru-Mian Zhang; Guo-Liang Chen; Wen-Qi Huang; Feng Min; Tian Chen; Jin-Chao Xu; Jin-Shui Pan
Journal:  PLoS One       Date:  2014-10-31       Impact factor: 3.240

2.  Serum transferrin as a liver fibrosis biomarker in patients with chronic hepatitis B.

Authors:  Hyo Jung Cho; Soon Sun Kim; Seun Joo Ahn; Joo Han Park; Dong Joon Kim; Young Bae Kim; Sung Won Cho; Jae Youn Cheong
Journal:  Clin Mol Hepatol       Date:  2014-12-24

3.  Noninvasive scoring system for significant inflammation related to chronic hepatitis B.

Authors:  Mei-Zhu Hong; Linglong Ye; Li-Xin Jin; Yan-Dan Ren; Xiao-Fang Yu; Xiao-Bin Liu; Ru-Mian Zhang; Kuangnan Fang; Jin-Shui Pan
Journal:  Sci Rep       Date:  2017-03-10       Impact factor: 4.379

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.